tradingkey.logo

Pfizer Inc

PFE

22.970USD

-1.300-5.35%
收盘 04/04, 16:00美东报价延迟15分钟
130.17B总市值
16.21市盈率 TTM

Pfizer Inc

22.970

-1.300-5.35%
关于 Pfizer Inc 公司
辉瑞公司是一家以研究为基础的全球生物制药公司。该公司在全球范围内从事生物制药产品的发现、开发、制造、营销、销售和分销。其生物制药部门从事以科学为基础的生物制药业务。其生物制药部门包括辉瑞肿瘤部门、辉瑞美国商业部门和辉瑞国际商业部门。其产品类别包括肿瘤、初级保健和专科护理。其肿瘤产品包括 Ibrance、Xtandi、Inlyta、Bosulif、Lorbrena、Braftovi、Mektovi、Padcev、Adcetris、Talzenna、Tukysa、Elrexfio 和 Tivdak。其初级保健产品包括 Eliquis、Nurtec ODT/Vydura、Comirnaty、Prevnar 家族、Abrysvo、FSME/IMMUN-TicoVac、Paxlovid 和 Lucira by Pfizer。其专科护理产品包括 Xeljanz、Enbrel(美国和加拿大以外)、Inflectra、Cibinqo、Litfulo、Vyndaqel 系列、Genotropin、Sulperazon、Zavicefta、Medrol 和 Panzyga。
公司简介
公司代码PFE
公司名称Pfizer Inc
上市日期Jan 17, 1944
成立日期1942
CEODr. Albert Bourla, Ph.D.
员工数量81000
证券类型Ordinary Share
年结日Jan 17
公司地址66 Hudson Boulevard East
城市NEW YORK
上市交易所NYSE Consolidated
国家United States of America
邮编10001-2192
电话12127332323
网址https://www.pfizer.com/
公司代码PFE
上市日期Jan 17, 1944
成立日期1942
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca, Ph.D.
Ms. Lidia L. Fonseca, Ph.D.
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+7.80K%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca, Ph.D.
Ms. Lidia L. Fonseca, Ph.D.
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
收入明细
单位: USD更新时间: 5 小时前
单位: USD更新时间: 5 小时前
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Eliquis alliance revenues and direct sales
7.37B
11.58%
Prevnar family
6.41B
10.08%
Paxlovid
5.72B
8.98%
Vyndaqel family
5.45B
8.57%
Comirnaty
5.35B
8.41%
Other
33.33B
52.38%
地区USD
名称
营收
占比
United States
38.69B
60.81%
Developed Markets
16.06B
25.24%
Emerging Markets
8.88B
13.95%
业务
地区
业务USD
名称
营收
占比
Eliquis alliance revenues and direct sales
7.37B
11.58%
Prevnar family
6.41B
10.08%
Paxlovid
5.72B
8.98%
Vyndaqel family
5.45B
8.57%
Comirnaty
5.35B
8.41%
Other
33.33B
52.38%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.10%
State Street Global Advisors (US)
5.12%
BlackRock Institutional Trust Company, N.A.
4.93%
Charles Schwab Investment Management, Inc.
2.74%
Wellington Management Company, LLP
2.47%
Other
75.64%
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.10%
State Street Global Advisors (US)
5.12%
BlackRock Institutional Trust Company, N.A.
4.93%
Charles Schwab Investment Management, Inc.
2.74%
Wellington Management Company, LLP
2.47%
Other
75.64%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
31.00%
Investment Advisor
24.83%
Research Firm
3.03%
Pension Fund
2.13%
Bank and Trust
1.87%
Hedge Fund
1.73%
Sovereign Wealth Fund
1.64%
Insurance Company
1.18%
Foundation
0.11%
Other
32.48%
机构持股
更新时间: 2月21日 周五
更新时间: 2月21日 周五
报告期
机构数
持股数
持股占比
持股变动
2025Q1
4957
3.85B
67.86%
-71.18M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.02B
71.16%
-62.35M
2023Q1
4947
4.02B
71.28%
-30.98M
2022Q4
4927
4.01B
71.39%
-30.90M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
515.98M
9.1%
+2.34M
+0.46%
Dec 31, 2024
State Street Global Advisors (US)
290.48M
5.12%
+23.75K
+0.01%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
279.54M
4.93%
+4.29M
+1.56%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
155.46M
2.74%
+25.32M
+19.45%
Dec 31, 2024
Wellington Management Company, LLP
139.99M
2.47%
-23.74M
-14.50%
Dec 31, 2024
Geode Capital Management, L.L.C.
120.59M
2.13%
+2.92M
+2.48%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
87.79M
1.55%
+3.82M
+4.55%
Dec 31, 2024
MFS Investment Management
74.22M
1.31%
+5.45M
+7.92%
Dec 31, 2024
State Farm Insurance Companies
54.51M
0.96%
--
--
Dec 31, 2024
BlackRock Asset Management Ireland Limited
45.96M
0.81%
+2.00M
+4.55%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
First Trust NASDAQ Pharmaceuticals ETF
7.69%
First Trust Morningstar Dividend Leaders Index Fund
7.46%
Parnassus Value Select ETF
6.15%
Amplify Weight Loss Drug & Treatment ETF
5.44%
Invesco Pharmaceuticals ETF
5%
NYLI Healthy Hearts ETF
4.77%
Vaneck Durable High Dividend ETF
4.65%
VanEck Pharmaceutical ETF
4.65%
ProShares Smart Materials ETF
4.3%
VanEck Morningstar Wide Moat Value ETF
4.28%
查看更多
First Trust NASDAQ Pharmaceuticals ETF
占比7.69%
First Trust Morningstar Dividend Leaders Index Fund
占比7.46%
Parnassus Value Select ETF
占比6.15%
Amplify Weight Loss Drug & Treatment ETF
占比5.44%
Invesco Pharmaceuticals ETF
占比5%
NYLI Healthy Hearts ETF
占比4.77%
Vaneck Durable High Dividend ETF
占比4.65%
VanEck Pharmaceutical ETF
占比4.65%
ProShares Smart Materials ETF
占比4.3%
VanEck Morningstar Wide Moat Value ETF
占比4.28%
分红派息
近5年累计派现 44.91B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
Apr 26, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023
May 12, 2023
Jun 09, 2023
May 11, 2023
Dec 09, 2022
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023
Jan 27, 2023
Mar 03, 2023
Jan 26, 2023
Sep 22, 2022
PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022
Nov 04, 2022
Dec 05, 2022
Nov 03, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
tradingkey.logo
tradingkey.logo
日内数据由路孚特(Refinitiv)提供,并受使用条款约束。历史及当前收盘数据均由路孚特提供。所有报价均以当地交易所时间为准。美股报价的实时最后成交数据仅反映通过纳斯达克报告的交易。日内数据延迟至少15分钟或遵循交易所要求。
* 参考、分析和交易策略由第三方提供商Trading Central提供,观点基于分析师的独立评估和判断,未考虑投资者的投资目标和财务状况。
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有